/GSK
GSK Stock - GSK plc
Healthcare|Drug Manufacturers - GeneralNYSE
$48.61+0.66%
+$0.32 (+0.66%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.83
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).68
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+9.0%upside
Target: $52.98
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GSK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$48.12 – $49.10
TARGET (TP)$53.00
STOP LOSS$44.72
RISK/REWARD1:1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.23
52W High$49.44
52W Low$31.72
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $31.38B | $30.33B | $29.32B | $24.70B | $24.35B |
| Gross Profit | $22.33B | $21.76B | $19.77B | $16.53B | $16.43B |
| Gross Margin | 71.2% | 71.8% | 67.4% | 66.9% | 67.4% |
| Operating Income | $4.02B | $6.75B | $6.43B | $4.36B | $5.98B |
| Net Income | $2.58B | $4.93B | $14.96B | $4.38B | $5.75B |
| Net Margin | 8.2% | 16.2% | 51.0% | 17.8% | 23.6% |
| EPS | $1.26 | $2.44 | $2.44 | $2.74 | $2.88 |
Company Overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
27%
Hold / Neutral
14
64%
Sell / Underperform
2
9%
Analyst Consensus🔴 Bearish
6 Bullish16 Neutral/Bearish
Price Targets
$41
Average Target
↓ 15.1% Downside
Now
$34
Low
$41
Average
$48
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 25th 2025 | BofA Securities | Upgrade | Neutral | - |
| June 3rd 2025 | Berenberg | Downgrade | Hold | - |
| April 15th 2025 | Exane BNP Paribas | Initiation | Neutral | $35.25 |
| February 12th 2025 | Morgan Stanley | Initiation | Equal Weight | - |
| November 15th 2024 | Deutsche Bank | Downgrade | Hold | - |
| November 12th 2024 | Jefferies | Downgrade | Hold | $39.5← $53 |
| October 31st 2024 | Guggenheim | Downgrade | Neutral | - |
| July 8th 2024 | UBS | Downgrade | Neutral | - |
| May 30th 2024 | Goldman | Initiation | Neutral | $47 |
| March 4th 2024 | Guggenheim | Upgrade | Buy | - |
| February 13th 2024 | Citigroup | Upgrade | Buy | - |
| January 23rd 2024 | Morgan Stanley | Initiation | Equal Weight | $44 |
| January 16th 2024 | UBS | Resumed | Buy | - |
| January 3rd 2024 | Jefferies | Upgrade | Buy | $48 |
| July 14th 2023 | HSBC Securities | Initiation | Reduce | - |
Earnings History & Surprises
GSKBeat Rate
94%
Last 16 quarters
Avg Surprise
+15.2%
EPS vs Estimate
Beats / Misses
15/1
Last 12 quarters
Latest EPS
$1.48
Q4 2025
EPS Surprise History
Q1 24
-5.3%
$0.72vs$0.76
Q3 24
+9.0%
$1.09vs$1.00
Q4 24
+9.5%
$1.27vs$1.16
Q1 25
+34.1%
$0.59vs$0.44
Q2 25
+4.6%
$1.13vs$1.08
Q3 25
No data
Q4 25
No data
Q4 25
+17.5%
$1.48vs$1.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $0.66 | — | — | — |
Q4 2025 | Oct 29, 2025 | $1.26 | $1.48 | +17.5% | ✓ BEAT |
Q4 2025 | Oct 29, 2025 | — | $0.98 | — | — |
Q3 2025 | Jul 30, 2025 | — | $0.96 | — | — |
Q2 2025 | Apr 30, 2025 | $1.08 | $1.13 | +4.6% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $0.44 | $0.59 | +34.1% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $1.16 | $1.27 | +9.5% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $1.00 | $1.09 | +9.0% | ✓ BEAT |
Q1 2024 | Jan 31, 2024 | $0.76 | $0.72 | -5.3% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $1.09 | $1.26 | +15.6% | ✓ BEAT |
Q3 2023 | Jul 26, 2023 | $0.87 | $0.97 | +11.5% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $0.82 | $0.90 | +9.8% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $0.59 | $0.64 | +8.5% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.96 | $1.10 | +14.6% | ✓ BEAT |
Q3 2022 | Jul 27, 2022 | $0.76 | $0.87 | +14.5% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $0.96 | $1.10 | +14.6% | ✓ BEAT |
Q1 2022 | Feb 9, 2022 | $0.81 | $0.86 | +6.2% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $1.00 | $1.26 | +26.0% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.64 | $0.98 | +53.1% | ✓ BEAT |
Latest News
GSK Says Agreements Provide Clarity To Both Companies On The Future Us Pricing Framework, And Exclude GSK And VIIV From S232 Tariffs For 3 Years; To Make Most Of Inhaled Respiratory Portfolio, Other Products Available To U.S. Patients On Direct Purchasing Platform With Savings Of Up To 66%; Detailed Terms Of The Agreements With The U.S. Remain Confidential
📈 PositiveBenzinga•Dec 19, 2025, 08:13 PM
GSK Enters Agreement With U.S. Government To Lower Drug Prices And Expand Access To Respiratory Medicines For Millions Of Americans; Deal Includes Products Used To Treat More Than 40 Million Patients In The U.S. Who Suffer From Respiratory Conditions Such As Asthma And COPD; GSK Will Further Support The Resilience Of The U.S. Supply Chain For Critical Medicines By Securing For The U.S. A Reserve Of Albuterol
📈 PositiveBenzinga•Dec 19, 2025, 08:12 PM
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralBenzinga•Dec 19, 2025, 07:30 PM•Also: , ,
Senior Administration Official Says President Trump To Announce Deals With Nine Pharmaceutical Companies To Reduce Drug Prices; Deals Are With Amgen, Bristol Myers Squibb, Roche's GenenTech, Gilead, GSK, Merck, Novartis, Sanofi And Boehringer Ingelheim; Each Manufacturer Agrees To Reduce Prices On Majority Of Medications Sold Through Medicaid; Companies Commit To $150B In New Investment In Manufacturing And R&D In U.S.
📈 PositiveBenzinga•Dec 19, 2025, 07:20 PM•Also: , ,
'Drug Companies Line Up To Make Deals With Trump After Initial Hesitation; At Least Seven Drug Companies Are Set To Announce Price Cuts With Trump At White House On Friday, Including GlaxoSmithKline, Merck And Sanofi' - Washington Post
📈 PositiveBenzinga•Dec 19, 2025, 05:40 PM•Also: ,
Spero Therapeutics Announces GSK Files New Drug Application Resubmission to FDA For Tebipenem HBr To Treat Complicated Urinary Tract Infections
📈 PositiveBenzinga•Dec 19, 2025, 01:13 PM•Also:
UPDATE: CAMP4 Therapeutics Partners With GSK To Develop ASO Therapies For Neurodegenerative And Renal Diseases; Secures $17.5M Upfront
📈 PositiveBenzinga•Dec 18, 2025, 01:32 PM•Also:
CAMP4 Therapeutics Enters Into Strategic Research, Collaboration And License Agreement With GSK To Identify, Develop ASO Drug Candidates For Multiple Gene Targets Relevant To Neurodegenerative And Kidney Disease Indications
📈 PositiveBenzinga•Dec 18, 2025, 12:03 PM•Also:
Reported Earlier, FDA Approves Exdensur As The First Ultra-Long-Acting Biologic For Severe Asthma With Eosinophilic Phenotype
📈 PositiveBenzinga•Dec 17, 2025, 06:28 AM
The European Medicines Agency's Committee For Medicinal Products For Human Use Has Recommended Expanding GSK's Adjuvanted Recombinant Respiratory Syncytial Virus Vaccine To All Adults Aged 18 Years And Older; The European Commission's Final Decision Is Expected In February 2026
📈 PositiveBenzinga•Dec 12, 2025, 09:48 AM
FDA Approves GSK's Blujepa For Uncomplicated Urogenital Gonorrhea In Some Adult & Pediatric Patients 12 Years Of Age & Older
📈 PositiveBenzinga•Dec 11, 2025, 05:39 PM
The FDA Granted Orphan Drug Designation To GSK's GSK'227 (Risvutatug Rezetecan) For Small-Cell Lung Cancer
📈 PositiveBenzinga•Dec 10, 2025, 10:05 AM
On December 4, 2025 GSK Terminated Collaboration With IDEAYA Biosciences; GSK Will Transfer The Werner Helicase And Pol Theta Clinical Programs To The Co In Accordance With The Applicable Provisions Of The Agreement; IDEAYA Biosciences Will Evaluate Its Strategic Options For These Two Programs In 2026, And The Update Does Not Change Its Expectation Of Cash Runway Into 2030
📉 NegativeBenzinga•Dec 5, 2025, 09:26 PM•Also:
CDC Prevention Advisory Committee On Immunization Practices Voted To Abandon Universal Hepatitis B Vaccination For Newborns
📉 NegativeBenzinga•Dec 5, 2025, 03:43 PM•Also: ,
GSK's Long-Term Data From DREAMM-7, DREAMM-8 Demonstrate Benefits Of Belantamab Mafodotin To Treat Relapsed Or Refractory Multiple Myeloma
📈 PositiveBenzinga•Dec 1, 2025, 02:57 PM
AnaptysBio drops after litigation with GSK unit risks cancer therapy deal
📉 NegativeSeeking Alpha•Nov 21, 2025, 12:10 PM•Also:
GSK Subsidiary Tesaro Initiates Litigation Against AnaptysBio Over Material Breach Of Jemperli License Agreement
📉 NegativeBenzinga•Nov 21, 2025, 08:55 AM•Also:
SCYNEXIS Completes Transfer Of BREXAFEMME New Drug Application To GSK
📈 PositiveBenzinga•Nov 19, 2025, 12:09 PM•Also:
AN2 Therapeutics Announces Collaboration Agreement With GSK To Develop New Therapies For TB
📈 PositiveBenzinga•Nov 10, 2025, 12:11 PM•Also:
GSK rises on higher profit growth projected for 2025
📈 PositiveSeeking Alpha•Oct 29, 2025, 02:25 PM
Frequently Asked Questions about GSK
What is GSK's current stock price?
GSK plc (GSK) is currently trading at $48.61 per share. The stock has moved +0.66% today.
What is the analyst price target for GSK?
The average analyst price target for GSK is $53.00, based on 1 analyst.
What sector is GSK plc in?
GSK plc operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.
What is GSK's market cap?
GSK plc has a market capitalization of $98.84 billion, making it a large-cap company.
Does GSK pay dividends?
No, GSK plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBMY
Bristol-Myers Squibb Company
$54.19
Mkt Cap: $110.3B
CELG-RI
Bristol-Myers Squibb Company Ce
$0.04
Mkt Cap: $0.1B
CI
Cigna Corporation
$271.89
Mkt Cap: $72.6B
CVS
CVS Health Corporation
$77.72
Mkt Cap: $98.7B
ELV
Elevance Health Inc.
$340.69
Mkt Cap: $75.7B
HCA
HCA Healthcare, Inc.
$472.98
Mkt Cap: $114.8B
MCK
McKesson Corporation
$820.25
Mkt Cap: $102.5B
SNY
Sanofi
$48.18
Mkt Cap: $117.4B
VRTX
Vertex Pharmaceuticals Incorporated
$456.20
Mkt Cap: $117.1B
ZTS
Zoetis Inc.
$122.24
Mkt Cap: $53.9B
Explore stocks similar to GSK for comparison